<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682435</url>
  </required_header>
  <id_info>
    <org_study_id>MMC0702028</org_study_id>
    <nct_id>NCT00682435</nct_id>
  </id_info>
  <brief_title>Safety Study of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg for Adult ED Patients</brief_title>
  <official_title>Safety and Speed of Onsent of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg in the Treatment of Adult ED Patients With Moderate to Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We wish to examine the safety and speed of onset of giving a dose of 1mg hydromorphone
      followed by an additional 1mg. Eligible patients will be given 1 mg intravenous (IV)
      hydromorphone. At 15 minutes, these patients will be asked the question, &quot;Do you need more
      pain medication?&quot; Those that answer &quot;yes&quot; will receive an additional 1mg IV hydromorphone.
      Those that answer &quot;no&quot; will not receive additional pain medications at that time period (15
      minutes). Thus, we wish to give up to 2 mg IV hydromorphone titrated to patients' pain, which
      we believe will result in less incidence of oxygen desaturation.

      If our study shows that this regimen is safe, its efficacy can be assessed in future trials.
      Positive results of those trials may lead to the use of this regimen to improve pain
      management in the emergency department.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective interventional study at an urban academic emergency department (ED). One
      milligram of IV hydromorphone was administered to adults 21 to 64 years of age who had acute
      severe pain. Fifteen minutes later, patients were asked whether they wanted more pain
      medication. If they answered yes, they received another 1 mg of IV hydromorphone and were
      again asked 15 minutes later whether they wanted more pain medication. The primary efficacy
      outcome was the proportion of patients who had adequate analgesia, defined as declining
      additional hydromorphone within 1 hour of entering the protocol. The primary safety outcome
      was incidence of oxygen desaturation less than 95%. Secondary outcomes included numeric
      rating scale pain scores and adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Had Adequate Analgesia</measure>
    <time_frame>60 minutes after medication infused</time_frame>
    <description>Adequate analgesia is defined as declining additional hydromorphone within 1 hour of entering the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Oxygen Desaturation Less Than 95%</measure>
    <time_frame>120 minutes after medication infused</time_frame>
    <description>primary safety outcome, defined as number of participants who experienced oxygen saturation &lt; 95%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Reduction in Pain Intensity</measure>
    <time_frame>60 minutes after medication infused</time_frame>
    <description>Pain intensity is measured on the numerical rating scale (NRS), with a pain score from 0 (no pain) to 10 (worst pain imaginable). The reduction in pain intensity is defined here as a change in pain score by 2 or more units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Intensity</measure>
    <time_frame>60 minutes after medication infused</time_frame>
    <description>Pain intensity is measured on the numerical rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable) from baseline to 60 minutes after medication infused</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Hydromorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
    <arm_group_label>Hydromorphone</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than 21 years: Patients under the age of 21 are automatically triaged to
             the Children's Hospital at Montefiore Emergency Department, and hence cannot be
             enrolled in this study.

          2. Age less than 65 years of age: Patients age 65 and over will be excluded in this study
             as the effects on opioids on the elderly may be different than in the non-elderly.

          3. Pain with onset within 7 days: Pain within seven days is the definition of acute pain
             that has been used in ED literature.

          4. ED attending physician's judgment that patient's pain warrants use of morphine: The
             factors that influence the decision to use parenteral opioids are complex and
             extensive. An approach that is commonly taken to address the issue of patient
             selection in drug trials is to use a specific condition (e.g., renal colic) or
             treatment (e.g., post-hysterectomy) that would generally be thought to be
             appropriately treated with an opioid analgesic, thereby eliminating individual
             judgment about eligibility for the study. However in order to assess the role of
             hydromorphone with the widest generalizability in the ED setting, we decided to enroll
             patients with a variety of diagnoses, all with a complaint of acute pain. Opioids are
             not an appropriate treatment for all patients who present with a complaint of pain
             (e.g., gastroenteritis, migraine). Therefore, unless there is a restriction to
             patients with a specific diagnosis, either a comprehensive list of diagnoses and
             situations in which opioids are indicated must be specified, or clinical judgment
             needs to be used. We have opted for the latter alternative.

          5. The use of patients with a variety of diagnoses, and therefore heterogeneous painful
             stimuli, risks masking a treatment effect because of large inter-individual
             variability. There are several design and analytic factors (detailed below) that
             attenuate this risk: 1) a sufficiently large number of patients will be randomly
             assigned to each group so that the variety of painful stimuli will be equally
             distributed between treatment groups; 2) change in pain intensity and pain relief will
             be analyzed rather than absolute pain intensity or pain relief therefore reducing
             variability.

          6. Normal mental status: In order to provide measures of pain experienced the patient
             needs to have a normal mental status. Orientation to person, place and time will be
             used as an indicator of sufficiently normal mental status to participate in the study.

        Exclusion Criteria:

          1. Prior use of methadone: the effect of methadone use on the perception of acute pain is
             unknown and suspected to be altered. We feel that the needs of patients on methadone
             may exceed the dosage ceiling of 2mg that will be used for this study. Similar to
             sickle cell patients and chronic cancer patients, patients on methadone usually
             require significantly higher doses of opioids to control their pain. Thus, we feel
             that it would be unethical to restrict the dose that this subset of patients can
             receive.

          2. Use of other opioids or tramadol within past seven days: to avoid introducing bias
             related to opioid tolerance that may alter the response to the study medication
             thereby masking the medication's effect.

          3. Prior adverse reaction to hydromorphone.

          4. Chronic pain syndrome: frequently recurrent or daily pain for at least 3 months result
             in alteration in pain perception which is thought to be due to down-regulation of pain
             receptors. Examples of chronic pain syndromes include sickle cell anemia,
             osteoarthritis, fibromyalgia, migraine, and peripheral neuropathies.

          5. Alcohol intoxication: the presence of alcohol intoxication as judged by the treating
             physician may alter perception, report, and treatment of pain.

          6. Systolic Blood Pressure &lt;90 mm Hg: Hydromorphone can produce peripheral vasodilation
             that may result in orthostatic hypotension or syncope.

          7. Oxygen saturation &lt;95% on room air: For this study, oxygen saturation must be 95% or
             above on room air in order to be enrolled.

          8. Use of monoamine oxidase (MAO) inhibitors in past 30 days: MAOs have been reported to
             intensify the effects of at least one opioid drug causing anxiety, confusion and
             significant respiratory depression or coma.

          9. C02 measurement greater than 46: In accordance with a similar study (04-12-360), three
             subsets of patients will have their CO2 measured using a handheld capnometer prior to
             enrollment in the study. If the CO2 measurement is greater than 46, then the patient
             will be excluded from the study. The 3 subsets are as follows:

               1. All patients who have a history of chronic obstructive pulmonary disease (COPD)

               2. All patients who report a history of asthma together with greater than a 20
                  pack-year smoking history

               3. All patients reporting less than a 20 pack-year smoking history who are having an
                  asthma exacerbation

         10. Pregnancy: this will be determined by asking the female of reproductive age about her
             pregnancy status and/or through the results of urine or serum pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Chang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Motefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 19, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <results_first_submitted>March 23, 2018</results_first_submitted>
  <results_first_submitted_qc>August 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2018</results_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Andrew Chang, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Nonelderly patients with acute moderate to severe pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydromorphone</title>
          <description>1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
Hydromorphone: 1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ensured Enrolled Only Once</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Sufficient Data to Carry Out Analysis</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insufficient data</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Erroneously enrolled twice</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydromorphone</title>
          <description>1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
Hydromorphone: 1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="223"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="30" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179" lower_limit="147" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of pain</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Abdomen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain intensity</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>4-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants experiencing Nausea or Vomiting before baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Had Adequate Analgesia</title>
        <description>Adequate analgesia is defined as declining additional hydromorphone within 1 hour of entering the protocol</description>
        <time_frame>60 minutes after medication infused</time_frame>
        <population>Those given a second dose only included patients who wanted more pain medication 15 minutes after 1st dose. 7 patients did not receive the second dose, resulting in 44 patients analyzed instead of expected 51</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
Hydromorphone: 1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Had Adequate Analgesia</title>
          <description>Adequate analgesia is defined as declining additional hydromorphone within 1 hour of entering the protocol</description>
          <population>Those given a second dose only included patients who wanted more pain medication 15 minutes after 1st dose. 7 patients did not receive the second dose, resulting in 44 patients analyzed instead of expected 51</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes after 1st 1mg dose of IV hydromorphone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>wanted more pain medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not want more pain medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes after 2nd 1 mg dose of IV hydromorphone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>wanted more pain medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not want more pain medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Oxygen Desaturation Less Than 95%</title>
        <description>primary safety outcome, defined as number of participants who experienced oxygen saturation &lt; 95%</description>
        <time_frame>120 minutes after medication infused</time_frame>
        <population>Total of 223 split into patients who received only 1 mg of IV hydromorphone (179) and those who received 2 mg of IV hydromorphone</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
Hydromorphone: 1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Oxygen Desaturation Less Than 95%</title>
          <description>primary safety outcome, defined as number of participants who experienced oxygen saturation &lt; 95%</description>
          <population>Total of 223 split into patients who received only 1 mg of IV hydromorphone (179) and those who received 2 mg of IV hydromorphone</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 mg IV hydromorphone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 mg IV hydromorphone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Reduction in Pain Intensity</title>
        <description>Pain intensity is measured on the numerical rating scale (NRS), with a pain score from 0 (no pain) to 10 (worst pain imaginable). The reduction in pain intensity is defined here as a change in pain score by 2 or more units.</description>
        <time_frame>60 minutes after medication infused</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
Hydromorphone: 1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Reduction in Pain Intensity</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS), with a pain score from 0 (no pain) to 10 (worst pain imaginable). The reduction in pain intensity is defined here as a change in pain score by 2 or more units.</description>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Intensity</title>
        <description>Pain intensity is measured on the numerical rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable) from baseline to 60 minutes after medication infused</description>
        <time_frame>60 minutes after medication infused</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
Hydromorphone: 1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Intensity</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable) from baseline to 60 minutes after medication infused</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 mg Hydromorphone</title>
          <description>1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
Hydromorphone: 1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulse rate &lt; 60 beats/min</sub_title>
                <description>excludes patients with baseline pulse rate less than 60 beats/min</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>excludes patients who were nauseated or vomiting before administration of first 1 mg of IV hydromorphone</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>excludes patients who were nauseated or vomiting before administration of first 1 mg IV hydromorphone</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation &lt; 95%</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Respiratory rate &lt; 12 breaths/min</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Systolic blood pressure &lt; 100 mmHg</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Chang, MD, MS</name_or_title>
      <organization>Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center</organization>
      <phone>718-920-7464</phone>
      <email>achang@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

